Page last updated: 2024-12-06

acamprosate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acamprosate is a medication used to help people with alcohol use disorder (AUD) maintain abstinence. It is thought to work by modulating the activity of glutamate, a neurotransmitter that is involved in the rewarding effects of alcohol. Acamprosate is synthesized in several steps, starting from commercially available materials. It is administered orally, and is generally well-tolerated. Acamprosate has been shown to be effective in reducing relapse rates in people with AUD. It is often used in conjunction with other treatments, such as psychotherapy and support groups. Acamprosate is studied to better understand its mechanisms of action, to identify potential new drug targets for AUD, and to develop more effective and safe treatments for this disorder.'

Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID71158
CHEMBL ID1201293
CHEBI ID51041
SCHEMBL ID41983
MeSH IDM0128674

Synonyms (56)

Synonym
CHEBI:51041 ,
acamprosatum
3-acetamidopropane-1-sulfonic acid
acamprosato
acamprosate
77337-76-9
aotal (tn)
D07058
acamprosate (inn)
3-(acetylamino)propanesulphonic acid
acamprosato [inn-spanish]
acamprosatum [inn-latin]
acamprostate
hsdb 7358
einecs 278-667-4
acamprosate [inn:ban]
n-acetylhomotaurine
3-acetamido-1-propanesulfonic acid
DB00659
n-acetyl homotaurine
CHEMBL1201293
AKOS006272019
n4k14ygm3j ,
unii-n4k14ygm3j
acamprosate [who-dd]
1-propanesulfonic acid, 3-(acetylamino)-
acamprosate [vandf]
3-(acetylamino)propane-1-sulfonate
acamprosate [inn]
3-(acetylamino)propane-1-sulphonate
acamprosate [hsdb]
1-propanesulfonic acid,3-(acetylamino)-
n-(3-sulfopropyl)ethanimidic acid
gtpl7106
SCHEMBL41983
DTXSID3044259 ,
AFCGFAGUEYAMAO-UHFFFAOYSA-N
SR-01000944872-1
sr-01000944872
AS-64312
3-acetamido-1-propansulfonsaure
Q337668
HMS3743O03
n acetylhomotaurine
3-(acetylamino)propanesulphonicacid
1alpha hydroxyvitamin d3-d6 (26,26,26,27,27,27-d6)
CDA33776
CS-0009584
HY-B0681
F87571
acamprosatum (inn-latin)
n07bb03
dtxcid1024259
acamprosato (inn-spanish)
EN300-708768
3-acetamidopropane-1-sulfonicacid

Research Excerpts

Overview

Acamprosate is an effective and cost-effective medication for alcohol relapse prevention but poor adherence can limit its full benefit. It is a widely utilized, efficacious treatment for relapse prevention in alcohol-dependent patients; yet, little is known regarding its therapeutic mechanism of action.

ExcerptReferenceRelevance
"Acamprosate is a good choice, as it prevents relapse to drinking with a number needed to treat of 12."( Treatment of alcohol use disorder in patients with liver disease.
Askgaard, G; Nielsen, AS; Thiele, M, 2022
)
1.44
"Acamprosate is an anti-craving drug used for the pharmacotherapy of alcohol use disorder (AUD). "( Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study.
Biernacka, JM; Choi, DS; Frye, MA; Geske, JR; Ho, MF; Karpyak, VM; Li, H; Moon, I; Oesterle, TS; Seppala, MD; Skime, MK; Wei, L; Weinshilboum, RM; Zhang, C; Zhang, L, 2022
)
2.45
"Acamprosate is an effective and cost-effective medication for alcohol relapse prevention but poor adherence can limit its full benefit. "( Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT.
Boniface, S; Brobbin, E; Byford, S; Coleman, R; Coulton, S; Day, E; Dhital, R; Donoghue, K; Drummond, C; Farid, A; Hermann, L; Jordan, A; Kimergård, A; Koutsou, ML; Lingford-Hughes, A; Marsden, J; Neale, J; O'Neill, A; Phillips, T; Shearer, J; Sinclair, J; Smith, J; Strang, J; Weinman, J; Whittlesea, C; Widyaratna, K, 2023
)
2.58
"Acamprosate is a medication used to treat alcohol dependence. "( Determination of acamprosate in human plasma by UPLC-MS/MS: Application to therapeutic drug monitoring.
Kul, A; Ozdemir, M; Ozilhan, S; Sagirli, O, 2020
)
2.34
"Acamprosate is an FDA-approved medication for the treatment of alcoholism that is unfortunately only effective in certain patients. "( Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model.
Andres-Beck, LG; Choi, DS; Cvek, U; Germany, CE; Hinton, DJ; Nam, HW; Oliveros, A; Reker, AN; Shen, X; Trutschl, M; Wininger, KM, 2018
)
2.19
"Acamprosate is an indirect NMDAR antagonist used for patients with chronic alcohol dependence."( The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration.
Bähr, M; Doeppner, TR; Hermann, DM; Kaltwasser, B; Kilic, E; Pehlke, JR; Schlechter, J, 2015
)
1.43
"Acamprosate calcium is a highly soluble drug with low permeability that is used to maintain abstinence in alcohol-dependent patients. "( Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets.
Jeon, JW; Lee, DS; Lee, TW; Nam, TY; Oh, TO; Park, CW; Park, ES; Park, S; Rhee, YS, 2008
)
2.01
"Acamprosate is a widely utilized, efficacious treatment for relapse prevention in alcohol-dependent patients; yet, little is known regarding its therapeutic mechanism of action."( The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial.
Beck, O; Franck, J; Hammarberg, A; Jayaram-Lindström, N; Reid, MS, 2009
)
2.15
"Acamprosate is a widely utilized, efficacious treatment for relapse prevention in alcohol dependent patients. "( The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin.
Franck, J; Hammarberg, A; Jayaram-Lindström, N; Nylander, I; Reid, MS; Zhou, Q, 2009
)
2.16
"Acamprosate appears to be an effective and safe treatment strategy for supporting continuous abstinence after detoxification in alcohol dependent patients. "( Acamprosate for alcohol dependence.
Hackl-Herrwerth, A; Lehert, P; Leucht, S; Rösner, S; Soyka, M; Vecchi, S, 2010
)
3.25
"Acamprosate is a medication shown to be effective for the treatment of alcohol dependence. "( A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence.
Dackis, C; Kampman, KM; Lynch, KG; O'Brien, CP; Pettinati, HM; Sparkman, T, 2011
)
2.07
"Acamprosate is an effective and well-tolerated pharmacological adjunct to psychosocial treatment programmes."( Acamprosate and its efficacy in treating alcohol dependent adolescents.
Niederhofer, H; Staffen, W, 2003
)
3.2
"Acamprosate is a promising medication for the treatment of alcohol dependence in the US."( Acamprosate for the adjunctive treatment of alcohol dependence.
Guthrie, SK; Overman, GP; Teter, CJ,
)
3.02
"Acamprosate seems to be an effective treatment for alcohol dependence in a Brazilian population."( Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting.
Baltieri, DA; De Andrade, AG, 2004
)
3.21
"Acamprosate is a proven effective intervention in the treatment of alcohol dependence. "( Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
Geerlings, PJ; Koeter, MW; Lehert, P; van den Brink, W; Verheul, R, 2005
)
2.13
"Acamprosate is an abstinence-promoting drug widely used in the treatment of alcohol dependence but which has a mechanism of action that has remained obscure for many years. "( Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action.
De Witte, P; Koob, G; Littleton, J; Parot, P, 2005
)
2.02
"Acamprosate (Campral) is a drug used clinically for the treatment of alcoholism. "( The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system.
Adams, C; Cowen, MS; Kraehenbuehl, T; Lawrence, AJ; Vengeliene, V, 2005
)
2.05
"Acamprosate is a synthetic taurine analogue that seems to act centrally to restore the normal activity of glutamatergic neurotransmission altered by chronic alcohol exposure."( Acamprosate in the treatment of alcohol dependence.
Mason, BJ, 2005
)
2.49
"Acamprosate is a drug used in alcoholism treatment, due to its regulating effects in glutamatergic and GABA neurotransmission, and has never been used before in the treatment of tinnitus"( Tinnitus treatment with acamprosate: double-blind study.
Azevedo, AA; Figueiredo, RR,
)
1.16
"Acamprosate is a drug intended to help prevent relapse among patients with alcohol dependence."( Acamprosate and primitive reflexes.
Bankes, L; Brown, TM; Guzik, P, 2007
)
2.5
"Acamprosate is a relatively new drug that appears to be clinically useful in the treatment of alcohol dependence. "( Acamprosate in alcohol dependence: how does it work?
Littleton, J, 1995
)
3.18
"Acamprosate is an effective and well-tolerated pharmacological adjunct to psychosocial and behavioural treatment programmes for treatment of alcohol-dependent patients."( Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.
Fischer, F; Fleischhacker, WW; Lesch, OM; Nimmerrichter, A; Oberbauer, H; Platz, T; Potgieter, A; Walter, H; Whitworth, AB, 1996
)
2.1
"Acamprosate proved to be a safe and effective aid in treating alcohol-dependent patients and in maintaining the abstinence of patients during 2 years."( Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.
Mann, K; Sass, H; Soyka, M; Zieglgänsberger, W, 1996
)
2.05
"Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions."( Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study.
Gavrilovic, M; Le Bon, O; Lehert, P; Lion, K; Pelc, I; Verbanck, P, 1997
)
2.05
"Acamprosate is a putative anticraving drug used to maintain abstinence in alcohol-dependent patients. "( Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex.
al Qatari, M; Bouchenafa, O; Littleton, J, 1998
)
2.05
"Acamprosate is a new psychotropic drug used in the treatment of alcohol (ethanol)-dependence. "( Clinical pharmacokinetics of acamprosate.
Chabac, S; Durbin, P; Houin, G; Hulot, T; Potgieter, A; Saivin, S, 1998
)
2.03
"Acamprosate is an homotaurine derivative, structural analogue of Gamma amino butyric acid and upper homologue of taurine. "( [Acamprosate. From pharmacology to therapeutics].
Dabadie, H; Nalpas, B; Paccalin, J; Parot, P,
)
2.48

Effects

Acamprosate has a very weak toxicity attributable to the ingested dose of calcium. It has a significant beneficial effect in enhancing abstinence in recently detoxified, alcohol-dependent individuals.

Acamprosate has been found to enhance rates of complete abstinence and to increase percent days abstinent (PDA) from alcohol relative to placebo treatment. It has been commercially available in the USA since 2004 to treat alcohol dependence.

ExcerptReferenceRelevance
"Acamprosate has a significant beneficial effect in enhancing abstinence in recently detoxified, alcohol-dependent individuals."( The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.
Lehert, P; Mann, K; Morgan, MY, 2004
)
2.11
"Acamprosate has a different mechanism of action than other drugs used for maintenance of abstinence from alcohol and is generally well tolerated. "( Acamprosate campral for alcoholism.
, 2005
)
3.21
"Acamprosate has a very weak toxicity attributable to the ingested dose of calcium."( [Acamprosate. From pharmacology to therapeutics].
Dabadie, H; Nalpas, B; Paccalin, J; Parot, P,
)
1.76
"Acamprosate has been shown to decrease insomnia in abstinent patients."( Insomnia in Alcohol-Dependent Patients: Prevalence, Risk Factors and Acamprosate Effect: An Individual Patient Data Meta-Analysis.
Lehert, P; Perney, P, 2018
)
1.44
"Acamprosate has been available in the United States for treating alcohol use disorders (AUDs) for nearly a decade, yet few studies have examined its use within AUD treatment organizations. "( Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.
Knudsen, HK; Roman, PM, 2014
)
2.1
"Acamprosate has been widely used since the Food and Drug Administration approved the medication for treatment of alcohol use disorders (AUDs) in 2004. "( Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.
Biernacka, JM; Choi, DS; Frye, MA; Geske, JR; Hinton, DJ; Ho, AM; Karpyak, VM; Nam, HW; Prieto, ML; Weinshilboum, RM, 2015
)
2.09
"Acamprosate, which has been shown to down-regulate the glutamatergic system, may be particularly effective for relief drinkers."( Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Mann, K; Roos, CR; Witkiewitz, K, 2017
)
1.38
"Acamprosate has been found to enhance rates of complete abstinence and to increase percent days abstinent (PDA) from alcohol relative to placebo treatment. "( Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study.
Beier, N; Berger, L; Bohn, M; Brondino, M; Fisher, M; Ford, A; Garbutt, JC; Greco, J; Gwyther, R; Longo, L, 2013
)
2.21
"Acamprosate has been marketed in 24 countries. "( Acamprosate for the adjunctive treatment of alcohol dependence.
Guthrie, SK; Overman, GP; Teter, CJ,
)
3.02
"Acamprosate has a significant beneficial effect in enhancing abstinence in recently detoxified, alcohol-dependent individuals."( The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.
Lehert, P; Mann, K; Morgan, MY, 2004
)
2.11
"Acamprosate has been shown to be effective and safe in relapse prevention of alcoholism. "( [Acamprosate--new preclinical research aspects].
Mann, K; Spanagel, R, 2003
)
2.67
"Acamprosate has a different mechanism of action than other drugs used for maintenance of abstinence from alcohol and is generally well tolerated. "( Acamprosate campral for alcoholism.
, 2005
)
3.21
"As acamprosate and naloxone have been suggested to selectively affect different types of craving (withdrawal-craving versus reward-craving), we have tried to modulate craving-behaviour by maintaining two groups of rats under different conditions (isolated versus group-housed)."( Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats.
Herzig, V; Schmidt, WJ, 2005
)
1.17
"Acamprosate has demonstrated efficacy for treating alcohol dependence in European trials, but with a small effect size."( Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Johnson, BA, 2008
)
1.07
"Acamprosate has been commercially available in the USA since 2004 to treat alcohol dependence. "( Acamprosate in the treatment of alcohol dependence: clinical and economic considerations.
Crean, R; Mason, BJ, 2007
)
3.23
"Acamprosate has recently been introduced in relapse prophylaxis in weaned alcoholics. "( Acamprosate inhibits Ca2+ influx mediated by NMDA receptors and voltage-sensitive Ca2+ channels in cultured rat mesencephalic neurones.
Allgaier, C; Franke, H; Scheibler, P; Sobottka, H, 2000
)
3.19
"Acamprosate has a very weak toxicity attributable to the ingested dose of calcium."( [Acamprosate. From pharmacology to therapeutics].
Dabadie, H; Nalpas, B; Paccalin, J; Parot, P,
)
1.76

Actions

ExcerptReferenceRelevance
"Acamprosate caused 36% increase in stimulated lipid peroxidation only in NPF animals."( DIFFERENT RESPONSE OF ANTIOXIDANT DEFENSE SYSTEM TO ACAMPROSATE IN ETHANOL PREFERRING AND NON-PREFERRING RATS.
Ewertowska, M; Jodynis-Lieberti, J; Mikolajczak, PL; Murias, M; Okulicz-Kozaryn, I; Stacheck, B,
)
1.1

Treatment

Acamprosate treatment had no effect on basal or CRH-stimulated ACTH or cortisol secretion. Treatment decreased GECAT and increased Cease control rats, but increased GECat and decreased CEase in PRF animals.

ExcerptReferenceRelevance
"Acamprosate treatment partially or completely rescued all of the FXS phenotypes analyzed, according to dose. "( Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome.
Bantel, AP; Hutson, RL; Tessier, CR; Thompson, RL, 2018
)
3.37
"13 acamprosate-treated and 13 placebo-treated patients completed the treatment phase: of those withdrawn, 11 (1 vs 6) relapsed, 5 (3 vs 2) refused to continue treatment, 3 (1 vs 2) had concurrent illness, and 2 (1 vs 1) had adverse side-effects. "( Acamprosate and its efficacy in treating alcohol dependent adolescents.
Niederhofer, H; Staffen, W, 2003
)
2.38
"The acamprosate-treated group (n = 16) were given 666 mg t.d.s."( A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients.
Feeney, A; Feldtkeller, B; Lingford-Hughes, A; Nutt, D; Weinstein, A, 2003
)
1.06
"Acamprosate treatment had no effect on basal or CRH-stimulated ACTH or cortisol secretion."( Hypothalamic-pituitary-adrenal system regulation in recently detoxified alcoholics is not altered by one week of treatment with acamprosate.
Holsboer, F; Koller, G; Soyka, M; Spring, K; Zimmerman, U, 2004
)
1.25
"Acamprosate treatment decreased GECAT and increased Cease control rats, but increased GECAT and decreased CEase in PRF animals."( Acamprosate involvement in triacylglycerol hydrolysis and transacylation with cholesterol in chronically ethanol-drinking rats.
Kaminska, E; Mikolajczak, P; Okulicz-Kozaryn, I; Piorunska-Mikolajczak, A; Piorunska-Stolzmann, M, 2004
)
2.49
"94 acamprosate-treated and 85 placebo-treated patients completed the treatment phase: of those withdrawn, 104 (52 in each group) relapsed, 69 (33 vs 36, respectively) were lost to follow-up, 63 (31 vs 32) refused to continue treatment, 16 (15 vs 11) had concurrent illness, three (two vs one) died, ten (six vs four) had adverse side-effects, one (acamprosate treated) received the wrong medication, and three (placebo treated) were non-compliant."( Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.
Fischer, F; Fleischhacker, WW; Lesch, OM; Nimmerrichter, A; Oberbauer, H; Platz, T; Potgieter, A; Walter, H; Whitworth, AB, 1996
)
1.17
"Acamprosate treatment over 180 days was consistently more effective than placebo to maintain abstinence and to diminish relapse severity."( Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study.
Bignamini, A; Chabac, S; Janiri, L; Potgieter, A; Tempesta, E,
)
2.3
"Acamprosate treatment did not modify blood ethanol levels."( Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats.
Daoust, M; DeWitte, P; Durbin, P; Gewiss, M; Heidbreder, C; Legrand, E; Tran, G, 1992
)
2.45
"Treatment with acamprosate and its active moiety calcium (CaCl"( The effects of acamprosate on prefrontal cortical function are mimicked by CaCl2 and they are influenced by the history of alcohol exposure.
Kroener, S; Luo, Y; Manepalli, R; Melugin, PR; Munoz, C; Nofal, A; Phensy, A; Pradhan, G; Wu, F, 2022
)
1.41
"Treatment with acamprosate was found to accrue a net benefit of 21,301 BEF (528 €) per patient over a 24-month period in Belgium and lifetime benefit for each patient in Spain was estimated to be Pta."( A literature review of cost-benefit analyses for the treatment of alcohol dependence.
Duhig, A; Mohapatra, S; Patra, J; Popova, S; Rehm, J, 2011
)
0.71
"Treatment with acamprosate and psychosocial support, by promoting abstinence, improves the quality of life profile to levels comparable to those observed in healthy individuals."( Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support.
Landron, F; Lehert, P; Morgan, MY, 2004
)
0.89
"Treatment with acamprosate in dose 200mg/kg, p.o."( Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference.
Cwiek, W; Czarnecka, E; Dyr, W; Zalewska-Kaszubska, J, 2005
)
0.9
"Treatment with acamprosate, a compound used for relapse prevention treatment of alcoholism, was recently shown to be associated with increased plasma concentration of beta-endorphin in rats selectively bred for high alcohol preference. "( Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference.
Jahn, H; Kiefer, F; Nakovics, H; Otte, C; Wiedemann, K, 2006
)
0.99
"Pretreatment with acamprosate, but not naltrexone, for 10 days resulted in higher dialysate concentrations of the compound relative to saline-pretreated controls."( A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration.
Burattini, C; Gass, JT; Griffin, WC; Janak, PH; Kinder, JR; McGeehan, AJ; Olive, MF, 2008
)
0.92

Toxicity

ExcerptReferenceRelevance
" According to these observations, NR2B SSNAs are potent inhibitors of ethanol-withdrawal-induced neurotoxicity and considering that these agents have acceptable side effect profiles, they could be promising therapeutic candidates in the pharmacotherapy for physical signs of acute alcohol-withdrawal and associated neuronal damage."( NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones.
Farkas, S; Horváth, C; Kolok, S; Nagy, J; Szombathelyi, Z, 2004
)
0.32
" Both drugs are safe and acceptably tolerated but issues of compliance need to be addressed adequately to assure their usefulness in clinical practice."( Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
Amate, JM; Angeles, M; Bouza, C; Magro, A; Muñoz, A, 2004
)
0.59
"In the many clinical studies conducted in the alcoholism field with psychotropic drugs--and throughout the drug development field in medicine, where evaluation of adverse events can be incomplete, arbitrary or misleading--few standardized methods have been developed for assessing adverse events, whereas defining standardized methods for evaluating clinical efficacy is typical."( The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
Ait-Daoud, N; Johnson, BA; Roache, JD, 2005
)
0.33
"We standardized use of the SAFTEE with training, supervision and clear guidelines for its implementation, including development of a nomenclature for the typical adverse events associated with these medications and a format for examining symptom severity."( The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
Ait-Daoud, N; Johnson, BA; Roache, JD, 2005
)
0.33
"The COMBINE SAFTEE was incorporated into the Medical Management therapy and showed high fidelity with its utility, consistency of deliverability and flexibility in measuring adverse events in both the human laboratory and clinical trial settings using intervals that varied from daily to weekly use."( The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
Ait-Daoud, N; Johnson, BA; Roache, JD, 2005
)
0.33
" Adverse events and abstinence at last follow-up were compared by Student's t-test, Mann-Whitney U or chi-square test."( Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
Cheng, A; Habtemariam, Z; Kelleher, C; Lewis, H; Lovendoski, J; Strathie, K; Tyson, LD, 2022
)
2.16

Pharmacokinetics

Few pharmacokinetic data of acamprosate were available in Chinese population. No medication is approved for alcohol dependence in China. Reduction in sAPP (total) and sAPPα may be a novel pharmacodynamic property.

ExcerptReferenceRelevance
" The present study was, therefore, planned to confirm blood-barrier crossing by Ca AOTA and to study the drug's physicochemical and pharmacokinetic characteristics."( Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate.
Andre, D; Boismare, F; Boucly, P; Chabenat, C; Chretien, P; Daoust, M; Lhuintre, JP; Moore, N; Saligaut, C, 1988
)
0.27
" The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion."( Clinical pharmacokinetics of acamprosate.
Chabac, S; Durbin, P; Houin, G; Hulot, T; Potgieter, A; Saivin, S, 1998
)
0.59
" Thus, this is the first human pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone."( A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.
Boyeson, MG; Dixon, RM; Goodman, AM; Hameed, MH; Hulot, T; Hunter, JA; Mason, BJ; Wesnes, K, 2002
)
0.77
" Although commonly used in the treatment of alcohol dependence, there are still unanswered questions concerning the pharmacokinetic properties of acamprosate."( Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers.
Andersson, M; Beck, O; Brundin, L; Eksborg, S; Franck, J; Hammarberg, A; Jayaram-Lindström, N; Lindefeldt, A; Reid, MS, 2010
)
2
" This method was successfully applied to a pharmacokinetic study after oral administration of acamprosate 333 mg tablet in Indian healthy male volunteers."( A LC-MS analysis of acamprosate from human plasma: pharmacokinetic application.
Chakraborty, BS; Ghosh, C; Jha, V; Shinde, CP, 2011
)
0.91
" Reduction in sAPP (total) and sAPPα may be a novel pharmacodynamic property of acamprosate."( Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker.
Bowers, K; Erickson, CA; Lahiri, DK; Maloney, B; McDougle, CJ; Ray, B; Schaefer, TL; Sokol, DK; Wink, LK, 2014
)
1.03
"Few pharmacokinetic data of acamprosate were available in Chinese population and no medication is approved for alcohol dependence in China."( Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers.
Liang, M; Luo, Z; Mei, Y; Miao, J; Qin, Y; Shen, Y; Wang, Y, 2015
)
0.96
" Investigate the pharmacokinetic properties of acamprosate calcium in healthy Chinese male volunteers on single- and multiple-dose administration."( Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers.
Liang, M; Luo, Z; Mei, Y; Miao, J; Qin, Y; Shen, Y; Wang, Y, 2015
)
0.93
" In each stage, a 2-way crossover bioequivalence study was conducted to study the pharmacokinetic properties and bioequivalence of acamprosate calcium tablets on multiple dosing after standardized meals, single dosing under fasting conditions and fed conditions, respectively."( Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers.
Liang, M; Luo, Z; Mei, Y; Miao, J; Qin, Y; Shen, Y; Wang, Y, 2015
)
0.87
"Similar pharmacokinetic results of acamprosate calcium tablets in healthy Chinese volunteers were found as those in Caucasic population."( Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers.
Liang, M; Luo, Z; Mei, Y; Miao, J; Qin, Y; Shen, Y; Wang, Y, 2015
)
0.95

Bioavailability

The acamprosate bioavailability was close to 20%, the amount recovered in the faeces being around 80% of the administered dose. The study aimed to improve the bioavailability of the drug through modulation of its intestinal absorption.

ExcerptReferenceRelevance
" When administered orally as enteric-coated tablets at relatively high doses, this drug has a bioavailability of about 11%; however, the intestinal absorption mechanism has not been studied in depth."( Kinetic study of acamprosate absorption in rat small intestine.
Granero, L; Guerri, C; Martín-Algarra, RV; Más-Serrano, P; Polache, A,
)
0.47
"The purpose of this study was to explore the intestinal absorption mechanism of acamprosate and to attempt to improve the bioavailability (BA) of the drug through modulation of its intestinal absorption using two enhancers (polysorbate 80 and sodium caprate) based on in situ, in vitro and in vivo models and comparing the results obtained."( Assessment and modulation of acamprosate intestinal absorption: comparative studies using in situ, in vitro (CACO-2 cell monolayers) and in vivo models.
Cano-Cebrián, MJ; Granero, L; Guerri, C; Nalda-Molina, R; Polache, A; Zornoza, T, 2004
)
0.84
" The acamprosate bioavailability was close to 20%, the amount recovered in the faeces being around 80% of the administered dose."( Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats.
Cano-Cebrián, MJ; Granero, L; Hipólito, L; Polache, A; Zornoza, T, 2006
)
1.12
" In conclusion, it is suggested that retarded drug release from the tablets and the low drug permeability may result in poor absorption and erratic bioavailability of this drug in humans."( Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets.
Jeon, JW; Lee, DS; Lee, TW; Nam, TY; Oh, TO; Park, CW; Park, ES; Park, S; Rhee, YS, 2008
)
0.57

Dosage Studied

Acamprosate calcium (CAS 77337-73-6) is generally well tolerated, has a low propensity for drug interactions and may be used without dosage adjustment in patients with mild to moderate hepatic impairment.

ExcerptRelevanceReference
" Once rats had acquired the discrimination, the criterion for stimulus control was set as at least 90% ethanol- or vehicle appropriate responding during ten consecutive sessions, an ethanol dose-response test (0."( Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat.
Hundt, W; Spanagel, R; Zieglgänsberger, W, 1996
)
1.74
" In particular, issues addressed include alternative dosage regimens, necessary duration of treatment, employment of medications in combination, integration of pharmacologic agents with behavioral interventions, enhancement of patient compliance, and concurrent treatment of psychiatric comorbidity."( Advances in development of medications for alcoholism treatment.
Allen, JP; Litten, RZ, 1998
)
0.3
" The relative paucity of dose-response studies on naltrexone's effects in treating alcoholics is an important gap in the literature."( Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Ait-Daoud, N; Johnson, BA, 2000
)
0.31
" COMBINE incorporates a number of innovative design aspects, including a no-pill psychotherapy-alone condition, behavioral interventions that are both manual-guided and individualized, and pharmacotherapy dosing that is greater than in some previous trials."( Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
, 2003
)
0.32
" Physiological, subjective, and psychomotor measures were collected daily during each dosing cycle."( Alcohol effects during acamprosate treatment: a dose-response study in humans.
Brasser, SM; Houtsmuller, EJ; McCaul, ME, 2004
)
0.63
" Data from dose-response studies for acamprosate alone suggest that the augmentation of acamprosate plasma levels by co-administration of naltrexone may have clinical benefits."( Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Mason, BJ, 2005
)
0.91
"To study the pharmacokinetics of acamprosate calcium (CAS 77337-73-6) in healthy Chinese subjects after oral administration of three dosage levels, 12 healthy subjects were divided into three groups and given a single oral dose of 333 or 666 or 1332 mg acamprosate calcium (enteric coated tablet)."( Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels.
Liang, M; Qing, Y; Shang, B; Xu, F; Xu, G; Zou, Y, 2009
)
0.96
" Acamprosate was dosed at 1998 mg/day."( Acamprosate calcium as augmentation therapy for anxiety disorders.
Costello, A; Raza, S; Schwartz, TL; Siddiqui, UA, 2010
)
2.71
" Factors such as dosing frequency, potential adverse events, and availability of treatments may guide medication choice."( Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R, 2014
)
0.4
" Acamprosate is generally well tolerated, has a low propensity for drug interactions and may be used without dosage adjustment in patients with mild to moderate hepatic impairment, although dosage adjustments or contraindications are recommended in patients with renal impairment."( Acamprosate: A Review of Its Use in Alcohol Dependence.
Plosker, GL, 2015
)
2.77
" In each stage, a 2-way crossover bioequivalence study was conducted to study the pharmacokinetic properties and bioequivalence of acamprosate calcium tablets on multiple dosing after standardized meals, single dosing under fasting conditions and fed conditions, respectively."( Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers.
Liang, M; Luo, Z; Mei, Y; Miao, J; Qin, Y; Shen, Y; Wang, Y, 2015
)
0.87
" This dual nature of acamprosate suggests multiple molecular mechanisms may be involved in acamprosate function depending on the dosage used."( Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome.
Bantel, AP; Hutson, RL; Tessier, CR; Thompson, RL, 2018
)
2.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
neurotransmitter agentA substance used for its pharmacological action on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organosulfonic acidAn organic derivative of sulfonic acid in which the sulfo group is linked directly to carbon.
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (593)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (1.35)18.7374
1990's82 (13.83)18.2507
2000's241 (40.64)29.6817
2010's201 (33.90)24.3611
2020's61 (10.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 87.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index87.33 (24.57)
Research Supply Index6.68 (2.92)
Research Growth Index5.66 (4.65)
Search Engine Demand Index155.87 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (87.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials137 (20.79%)5.53%
Reviews186 (28.22%)6.00%
Case Studies10 (1.52%)4.05%
Observational1 (0.15%)0.25%
Other325 (49.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (40)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered SNC-102 in Subjects With Drug-Induced Tardive Dyskinesia [NCT02064010]Phase 20 participants (Actual)Interventional2014-02-28Withdrawn(stopped due to Funding terminated; company closed)
Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome [NCT03818191]Phase 4378 participants (Actual)Interventional2019-07-15Completed
Neurophysiological and Acute Pharmacological Studies in FXS Patients [NCT02998151]Early Phase 129 participants (Actual)Interventional2016-01-31Completed
Promoting Medications for Alcohol Use Disorder on the General Medicine Service at Yale New Haven Hospital: a Pilot Study [NCT04287790]67 participants (Actual)Observational2020-01-01Terminated(stopped due to COVID-19 disrupted recruitment)
Biomarker Study of Acamprosate in Schizophrenia [NCT00688324]Phase 436 participants (Actual)Interventional2008-06-30Completed
Pilot Study of Acamprosate in Youth With Fragile X Syndrome [NCT01300923]Phase 214 participants (Actual)Interventional2010-08-31Completed
A Probe Study of Acamprosate: Genes Associated With Response [NCT00662571]485 participants (Actual)Observational2008-05-31Completed
Open Label, Flexible Dose 12-Week Clinical Trial of the Safety and Efficacy of Acamprosate in the Treatment of Pathological Gambling [NCT00571103]Phase 426 participants (Actual)Interventional2007-10-31Completed
Clinical Trial of Acamprosate for Tinnitus [NCT00596531]Phase 1154 participants (Actual)Interventional2008-01-31Completed
Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease [NCT00640952]0 participants (Actual)Interventional2006-08-31Withdrawn(stopped due to PI left site)
Alcohol Detoxification in Primary Care Treatment (ADEPT) - a Feasibility Study of Conducting a Randomised Trial in Primary Care Comparing Two Pharmacological Regimens. [NCT00855699]Phase 436 participants (Actual)Interventional2009-11-30Completed
Campral (Acamprosate) Treatment of Alcohol Dependence in a Family Medicine Setting: A Randomized, Double-Blind Placebo-Controlled Study [NCT00381043]Phase 4100 participants (Actual)Interventional2006-08-31Completed
A Placebo-controlled, Double Blind, Randomized Trial of Acamprosate for the Treatment of Methamphetamine Dependence [NCT00571922]Phase 1/Phase 272 participants (Actual)Interventional2007-07-31Completed
Acamprosate and Integrative Behavior Therapy in the Outpatient Treatment of Alcohol Dependents [NCT00159107]Phase 4371 participants (Actual)Interventional2003-05-31Completed
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism [NCT00463346]Phase 323 participants (Actual)Interventional2006-09-30Completed
The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression [NCT00330174]Phase 490 participants (Actual)Interventional2006-04-30Completed
Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome [NCT01911455]Phase 146 participants (Actual)Interventional2013-08-27Completed
Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study [NCT00655967]Phase 40 participants (Actual)Interventional2006-12-31Withdrawn(stopped due to PI left the institution)
An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants [NCT00591565]13 participants (Actual)Interventional2006-06-30Completed
Phase Four Randomized, Multicentre, Open-Label, Comparative Trial Of Disulfiram, Nalterexone And Acamprosate In The Treatment Of Alcohol Dependence [NCT00435435]Phase 4243 participants Interventional2000-09-30Completed
COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions [NCT00006206]Phase 31,375 participants Interventional1997-08-31Completed
An Open-Label Study of Acamprosate in DUI Court Participants [NCT00425711]4 participants (Actual)Interventional2007-02-28Terminated(stopped due to Recruitment barriers.)
Initiating Acamprosate Within Versus Post-detoxification in the Rehabilitative Treatment of Alcohol Dependence. [NCT00360594]Phase 240 participants (Actual)Interventional2006-10-31Completed
A Double-Blind, Randomized, Placebo-Controlled Trial of Acamprosate in Alcohol-Dependent Individuals With Comorbid Bipolar Disorder [NCT00466661]Phase 433 participants (Actual)Interventional2007-04-30Completed
Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics [NCT00605904]Phase 237 participants (Actual)Interventional2008-01-31Completed
[NCT00511940]Phase 2/Phase 340 participants (Anticipated)Interventional2007-04-30Completed
The Role of Pharmacotherapy in Prevention of Relapse in Alcohol Dependence [NCT00120601]Phase 4200 participants Interventional2003-03-31Active, not recruiting
A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence [NCT00452543]Phase 423 participants (Actual)Interventional2007-03-31Completed
A Phase 2a, Open-Label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Tourette Syndrome [NCT02217007]Phase 20 participants (Actual)Interventional2015-04-30Withdrawn(stopped due to Funding stopped, company closed)
Individually Adapted Therapy of Alcoholism: Clinical Studies [NCT00317031]Phase 4435 participants (Actual)Interventional2002-11-30Completed
The Use of Acamprosate in Alcohol-Dependent Individuals With Bipolar Disorder [NCT00330486]Phase 1/Phase 29 participants (Actual)Interventional2006-04-30Completed
A Phase II, Double-Blind, Placebo-controlled, Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence [NCT00385268]Phase 260 participants (Actual)Interventional2006-11-30Completed
Double-Blind Placebo-Controlled Study of Acamprosate in Autism [NCT01813318]Phase 136 participants (Actual)Interventional2013-07-02Completed
Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence (TEMACA) [NCT03634917]Phase 384 participants (Anticipated)Interventional2020-08-05Recruiting
Etiology and Treatment of Alcohol Dependence [NCT00004552]Phase 2120 participants InterventionalCompleted
Acamprosate for Central Nervous System Hyperexcitability and Neuroadaptation in Alcohol Withdrawal [NCT00106106]Phase 256 participants (Actual)Interventional2005-03-31Completed
The Use of Acamprosate for Preventing Alcohol Relapse Among Alcohol Dependent Drug Treatment Court Participants [NCT00249379]Phase 426 participants (Actual)Interventional2005-06-30Terminated(stopped due to Not enough sugjects enrolled before funding ran out)
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
Medication Development in Protracted Abstinence in Alcoholism: Acamprosate Versus Naltrexone [NCT00656630]Phase 268 participants (Actual)Interventional2007-12-31Completed
A Randomized, Double-Blind, Placebo-Controlled Trial of Vortioxetine for Depressive Mood and Alcohol Use in Adults With Major Depressive Disorder and Alcohol Use Disorder [NCT04498897]Phase 2128 participants (Anticipated)Interventional2019-01-25Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00106106 (2) [back to overview]Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 25
NCT00106106 (2) [back to overview]Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4
NCT00249379 (4) [back to overview]Retention in Drug Court
NCT00249379 (4) [back to overview]Recidivism Rates
NCT00249379 (4) [back to overview]Level of Acceptance
NCT00249379 (4) [back to overview]Drinking and Other Drug Use
NCT00330174 (4) [back to overview]Hospital Anxiety and Depression Scale
NCT00330174 (4) [back to overview]Liebowitz Social Anxiety Scale
NCT00330174 (4) [back to overview]Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00330174 (4) [back to overview]Percent Days Drinking
NCT00381043 (7) [back to overview]% Dropout
NCT00381043 (7) [back to overview]% Heavy Drinking Days During Trial
NCT00381043 (7) [back to overview]Percent Days Abstinent
NCT00381043 (7) [back to overview]% Compliant With Medication
NCT00381043 (7) [back to overview]Clinical Global Impression Scale
NCT00381043 (7) [back to overview]Retention
NCT00381043 (7) [back to overview]Percent With Complete Abstinence
NCT00385268 (1) [back to overview]Cocaine Use Over the Eight Week Trial as Measured by Twice Weekly Urine Drug Screen
NCT00452543 (4) [back to overview]Total Drinks Consumed Per Week on the TLFB
NCT00452543 (4) [back to overview]Total Drinks Consumed Per Drinking Day on the TLFB
NCT00452543 (4) [back to overview]Total Drinking Days on the Alcohol Timeline Followback (TLFB)
NCT00452543 (4) [back to overview]Change in Mean Score on the Hamilton Rating Scale for Depression -- 17 Items (HAM-D-17)
NCT00463346 (2) [back to overview]Psychotic Symptoms - Measured Using the PANSS
NCT00463346 (2) [back to overview]Number of Drinking Days
NCT00466661 (9) [back to overview]Clinical Global Impression Scale Score
NCT00466661 (9) [back to overview]Percent Days Abstinent
NCT00466661 (9) [back to overview]Percent Heavy Drinking Days
NCT00466661 (9) [back to overview]Time to First Drink (Days)
NCT00466661 (9) [back to overview]Young Mania Rating Scale Score
NCT00466661 (9) [back to overview]Obsessive Compulsive Drinking Scale Score
NCT00466661 (9) [back to overview]Montgomery Asberg Depression Rating Scale Score
NCT00466661 (9) [back to overview]Gamma-glutamyltransferase
NCT00466661 (9) [back to overview]Percent Carbohydrate-deficient Transferrin
NCT00571103 (2) [back to overview]The Primary Efficacy Measure Was the Yale-Brown Obsessive Compulsive Scale Modified for PG (YBOCS-PG).
NCT00571103 (2) [back to overview]The Secondary Efficacy Evaluations Will Include the G-SAS (Gambling Symptom Assessment Scale), Clinical Global Impression - Improvement Scale (CGI-I) , and the CGI-S Clinical Global Impression - Severity Scale.
NCT00591565 (1) [back to overview]Change From Baseline at 8 Weeks in the HAM-A Scale
NCT00605904 (3) [back to overview]Alcohol Craving Rating in Response to Saline Infusion
NCT00605904 (3) [back to overview]Alcohol Craving Rating in Response to Yohimbine Infusion
NCT00605904 (3) [back to overview]Alcohol Craving Rating in Response to Meta-Chlorophenylpiperazine
NCT00656630 (5) [back to overview]Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Acamprosate or Naltrexone or Placebo During the Double-Blind Period
NCT00656630 (5) [back to overview]Change From Screening in Craving on the Alcohol Craving Questionnaire-Short Form (ACQ-SF) Total Score at Week 1
NCT00656630 (5) [back to overview]Change From Baseline in Standard Drinks Per Week at 1 Week
NCT00656630 (5) [back to overview]Change From Baseline in Mood on the Beck Depression Inventory (BDI-II) at Week 1
NCT00656630 (5) [back to overview]Change From Baseline in Sleep Quality on the Pittsburgh Sleep Quality Index (PSQI) Total Score at Week 1
NCT00688324 (20) [back to overview]Anterior Cingulate Cortex - Creatinine
NCT00688324 (20) [back to overview]Left Dorsal Lateral Prefrontal Cortex - N-acetylaspartate
NCT00688324 (20) [back to overview]Anterior Cingulate Cortex - Choline
NCT00688324 (20) [back to overview]Fractional Anisotropy Measured With Diffusion Tensor Imaging
NCT00688324 (20) [back to overview]SANS - Negative Symptoms of Schizophrenia Total Score
NCT00688324 (20) [back to overview]Right Dorsal Lateral Prefrontal Cortex - N-acetylaspartate
NCT00688324 (20) [back to overview]Right Dorsal Lateral Prefrontal Cortex - Myo-inositol
NCT00688324 (20) [back to overview]Right Dorsal Lateral Prefrontal Cortex - Glutamate
NCT00688324 (20) [back to overview]Right Dorsal Lateral Prefrontal Cortex - Creatinine
NCT00688324 (20) [back to overview]Right Dorsal Lateral Prefrontal Cortex - Choline
NCT00688324 (20) [back to overview]Left Dorsal Lateral Prefrontal Cortex - Myo-inositol
NCT00688324 (20) [back to overview]Left Dorsal Lateral Prefrontal Cortex - Glutamate
NCT00688324 (20) [back to overview]Left Dorsal Lateral Prefrontal Cortex - Creatinine
NCT00688324 (20) [back to overview]Left Dorsal Lateral Prefrontal Cortex - Choline
NCT00688324 (20) [back to overview]Anterior Cingulate Cortex - N-acetylaspartate
NCT00688324 (20) [back to overview]Cognitive Impairment
NCT00688324 (20) [back to overview]BPRS - Symptoms of Psychosis Total Score
NCT00688324 (20) [back to overview]BPRS - Symptoms of Psychosis Change in Scores
NCT00688324 (20) [back to overview]Anterior Cingulate Cortex - Myo-inositol
NCT00688324 (20) [back to overview]Anterior Cingulate Cortex - Glutamate
NCT01300923 (8) [back to overview]Social Responsiveness Scale
NCT01300923 (8) [back to overview]Clinical Global Impression- Severity Scale (CGI-S)
NCT01300923 (8) [back to overview]Children's Yale-Brown Obsessive Compulsive Scale Modified for PDD
NCT01300923 (8) [back to overview]The Aberrant Behavior Checklist (ABC)
NCT01300923 (8) [back to overview]Peabody Picture Vocabulary
NCT01300923 (8) [back to overview]ADHD Rating Scale 4th Edition
NCT01300923 (8) [back to overview]Brain-derived Neurotrophic Factor (BDNF)
NCT01300923 (8) [back to overview]Vineland Adaptive Behavior Scales-II (VABS-II) Communication Domain
NCT02998151 (5) [back to overview]Change in EEG Relative Gamma Power
NCT02998151 (5) [back to overview]Woodcock Johnson Test of Cognitive Abilities - Auditory Attention Task
NCT02998151 (5) [back to overview]Test of Attentional Performance for Children (KiTAP) Test of Alertness
NCT02998151 (5) [back to overview]Clinical Global Impressions-Improvement
NCT02998151 (5) [back to overview]Change From Pre-dose in the Repeatable Battery for the Assessment of Neuropsychological Status at 4 Hours Post Dose

Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 25

The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. (NCT00106106)
Timeframe: Day 25

InterventionRatio of glutamate to creatine (Mean)
Placebo1.350375
Acamprosate1.166667

[back to top]

Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4

The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. (NCT00106106)
Timeframe: Day 4

InterventionRatio of glutamate to creatine (Mean)
Placebo1.256772
Acamprosate1.294178

[back to top]

Retention in Drug Court

Number of participants remaining in drug treatment court program during 12 weeks (NCT00249379)
Timeframe: 12 weeks

Interventionparticipants (Number)
Acamprosate13

[back to top]

Recidivism Rates

Number of participants returning to jail during 12 weeks (NCT00249379)
Timeframe: 12 weeks

Interventionparticipants (Number)
Acamprosate5

[back to top]

Level of Acceptance

Number of participants taking study medication during 12 weeks (NCT00249379)
Timeframe: 12 weeks

Interventionparticipants (Number)
Acamprosate13

[back to top]

Drinking and Other Drug Use

Number of participants using alcohol and other drugs during 12 weeks (NCT00249379)
Timeframe: 12 weeks

Interventionparticipants (Number)
Acamprosate6

[back to top]

Hospital Anxiety and Depression Scale

This is a 14-item self report assessment that contains two subscales (depression and anxiety) with each subscale ranging from 0-21; the total score ranges from 0-42. We report total scores. Higher scores represent worse symptoms. (NCT00330174)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Acamprosate10.5
Placebo9.4

[back to top]

Liebowitz Social Anxiety Scale

The LSAS is a 24-item semi-structured clinician-administered instrument that assesses social anxiety through the evaluation of fear and avoidance of different social and performance situations. There are two subscales (avoidance and fear), with scores ranging from 0-72; Total score for instrument ranges from 0-144. This study only reports on total score. Higher scores reflect greater anxiety symptoms. (NCT00330174)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Acamprosate22.5
Placebo23.2

[back to top]

Montgomery-Asberg Depression Rating Scale (MADRS)

This 10-item rating scale is commonly used in the European pharmacotherapy trials, and it may have benefit in assessing substance abusers, because it focuses on cognitive symptoms of depression instead of the physical symptoms, which could be due to substance use and withdrawal (Yonkers and Samson, 2000). Total scores are used; Scale range is 0-60, with higher scores reflecting more severe symptoms. (NCT00330174)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Acamprosate11.0
Placebo11.5

[back to top]

Percent Days Drinking

Drinking was assessed using the timeline followback (TLFB), which is a calendar-based instrument used to assess drinking and other substance use on a daily basis. (NCT00330174)
Timeframe: 12 weeks

Interventionpercentage of days drinking (Mean)
Acamprosate34.9
Placebo31.9

[back to top]

% Dropout

Percentage of participants who dropped out of study by drug condition (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
1- Acamprosate21.5
2 - Sugar Pill - Placebo16.3

[back to top]

% Heavy Drinking Days During Trial

% of Heavy drinking days (5 or more drinks/d for a man or 4 or more drinks/d for a woman) over the 12 weeks of the trial. (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of heavy drinking days (Mean)
1- Acamprosate15.8
2 - Sugar Pill - Placebo18.4

[back to top]

Percent Days Abstinent

%Days without any alcohol consumption over the treatment period (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of days (Mean)
1- Acamprosate40.7
2 - Sugar Pill - Placebo41.6

[back to top]

% Compliant With Medication

% of individuals with evidence for 80% compliance with medication based on returned blister packs and weekly diaries. (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
1- Acamprosate93.3
2 - Sugar Pill - Placebo91.6

[back to top]

Clinical Global Impression Scale

Range of overall severity of illness: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill (NCT00381043)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
1- Acamprosate2.3
2 - Sugar Pill - Placebo2.4

[back to top]

Retention

Number of individuals retained in the trial by acamprosate vs placebo group (NCT00381043)
Timeframe: 12 weeks

Interventionparticipants (Number)
1- Acamprosate39
2 - Sugar Pill - Placebo41

[back to top]

Percent With Complete Abstinence

% of subjects with no drinking during the 12 week treatment trial (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
1- Acamprosate5.9
2 - Sugar Pill - Placebo19.1

[back to top]

Cocaine Use Over the Eight Week Trial as Measured by Twice Weekly Urine Drug Screen

cocaine abstinent weeks determined by all negative urine drug screens in each week (2 urine drug screens per week) (NCT00385268)
Timeframe: 8 weeks

Interventioncocaine abstinent weeks (Mean)
Acamprosate1.3
Placebo1.2

[back to top]

Total Drinks Consumed Per Week on the TLFB

Total Drinks Consumed per Week on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)

InterventionDrinks consumed per week (Mean)
Escitalopram Plus Acamprosate15
Escitalopram Plus Placebo15

[back to top]

Total Drinks Consumed Per Drinking Day on the TLFB

Total Drinks Consumed per Drinking Day on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)

InterventionDrinks consumed per drinking day (Mean)
Escitalopram Plus Acamprosate4
Escitalopram Plus Placebo4

[back to top]

Total Drinking Days on the Alcohol Timeline Followback (TLFB)

The TLFB assesses recent drinking behavior. On the TLFB, clients retrospectively estimate their daily alcohol consumption in standard drinks over a time period ranging from 7 days to 24 months prior to the interview, and thus the measure provides quantitative estimates of alcohol use. One standard drink on the TLFB was defined as: 12 oz beer (5% alcohol by volume), 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)

InterventionDrinking days (Mean)
Escitalopram Plus Acamprosate61
Escitalopram Plus Placebo61

[back to top]

Change in Mean Score on the Hamilton Rating Scale for Depression -- 17 Items (HAM-D-17)

Scores on the HAM-D-17 typically fall into the following ranges: a) Not depressed: 0-7; b) Mildly depressed: 7-15; c) Moderately depressed: 15-25; d) Severely depressed: over 25. A decrease of 50% or more in the Hamilton-D score is considered to be a positive response to treatment, while a score of 7 or less is considered typical of remission. We measure the change in total score from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From baseline visit to Week 12 (or early discontinuation visit)

InterventionScores on a scale (Mean)
Escitalopram Plus Acamprosate-5.6
Escitalopram Plus Placebo-7.8

[back to top]

Psychotic Symptoms - Measured Using the PANSS

The PANSS or the Positive and Negative Syndrome Scale is a medical scale used for measuring symptom severity of patients with schizophrenia. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Of the 30 items included in the PANSS, 7 constitute a Positive Scale, 7 a Negative Scale, and the remaining 16 a General Psychopathology Scale.The scores for these scales are arrived at by summation of ratings across component items. Therefore, the potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale. A higher score indicates more severe symptoms. (NCT00463346)
Timeframe: 12 weeks

,
Interventionunits on a scale (Mean)
PANSS positive symptomsPANSS negative symptomsPANSS general symptoms
Acamprosate14.51413.47628.083
Placebo14.36215.97129.33

[back to top]

Number of Drinking Days

(NCT00463346)
Timeframe: 12 weeks

Interventiondays (Mean)
Acamprosate10.7
Placebo7.6

[back to top]

Clinical Global Impression Scale Score

Higher values indicate worse outcomes; minimum value = 1, maximum value = 7 (NCT00466661)
Timeframe: 8 weeks

Interventionscore on a scale (Mean)
Acamprosate2.7
Placebo3.7

[back to top]

Percent Days Abstinent

Percentage of days in trial with no alcohol consumption (NCT00466661)
Timeframe: 8 weeks

Interventionpercentage of days in trial (Mean)
Acamprosate77.0
Placebo73.0

[back to top]

Percent Heavy Drinking Days

Percentage of drinking days that are heavy drinking days (5 or more standard drinks/day for males, 4 or more standard drinks/day for females) (NCT00466661)
Timeframe: 8 weeks

Interventionpercentage of days drinking (Mean)
Acamprosate6.4
Placebo10.7

[back to top]

Time to First Drink (Days)

Number of days after randomization until consumption of first alcoholic beverage per self-report. (NCT00466661)
Timeframe: 8 weeks

InterventionDays (Mean)
Acamprosate16.5
Placebo8.0

[back to top]

Young Mania Rating Scale Score

YMRS scores at study endpoint. Higher scores indicate a worse outcome. Minimum score = 0, maximum score = 60. (NCT00466661)
Timeframe: 8 weeks

Interventionscore on a scale (Mean)
Acamprosate5.3
Placebo5.4

[back to top]

Obsessive Compulsive Drinking Scale Score

Higher scores indicate worse outcome; minimum score = 0, maximum score = 40 (NCT00466661)
Timeframe: 8 weeks

Interventionscore on a scale (Mean)
Acamprosate10.8
Placebo15.3

[back to top]

Montgomery Asberg Depression Rating Scale Score

MADRS scores at study endpoint. Higher scores indicate a worse outcome. Minimum score = 0, maximum score = 60. (NCT00466661)
Timeframe: 8 weeks

Interventionscore on a scale (Mean)
Acamprosate8.7
Placebo11.3

[back to top]

Gamma-glutamyltransferase

Measured levels of validated serum alcohol biomarker (NCT00466661)
Timeframe: 8 weeks

InterventionGamma-glutamyltransferase U/L (Mean)
Acamprosate37.1
Placebo63.8

[back to top]

Percent Carbohydrate-deficient Transferrin

Measured level of validated serum alcohol biomarker (NCT00466661)
Timeframe: 8 weeks

Intervention"percent CDT" (Mean)
Acamprosate2.4
Placebo2.5

[back to top]

The Primary Efficacy Measure Was the Yale-Brown Obsessive Compulsive Scale Modified for PG (YBOCS-PG).

The YBOCS-PG (Yale Brown Obsessive Compulsive Scale modified for Pathological Gambling) is used to assess the range and severity of PG symptoms. The scale is a modification of the YBOCS originally developed by Goodman et al. (1989) for use in rating severity and change in subjects with Obsessive Compulsive Disorder. This adaptation is a 10-item clinician-rated questionnaire, which rates (on a 5-point scale from 0 to 4) time spent, distress, interference, resistance, and control in relation to PG urges and behaviors. The scale ranges from 0 to 40 with a higher score representing increased severity in PG. (NCT00571103)
Timeframe: 8 weeks minus baseline

Interventionunits on a scale (Mean)
Open Label-.985

[back to top]

The Secondary Efficacy Evaluations Will Include the G-SAS (Gambling Symptom Assessment Scale), Clinical Global Impression - Improvement Scale (CGI-I) , and the CGI-S Clinical Global Impression - Severity Scale.

The G-SAS is a 12 item self-report instrument that reflects the subjects urges to gamble and the subjects gambling behavior. Each item is scored on a 5-point scale from 0 (no symptoms) to 4 (extreme symptoms) with a total score range from 0 to 48. The CGI-I is a 7 point scale requiring the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment. A patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; and 7, among the most extremely ill patients. (NCT00571103)
Timeframe: 8 weeks minus baseline

Interventionunits on a scale (Mean)
G-SASCGI-ICGI-S
Open Label-1.117-.145-.199

[back to top]

Change From Baseline at 8 Weeks in the HAM-A Scale

this is a validated clinician administered scale that can range from 0-44 (mild to severe illness). (NCT00591565)
Timeframe: baseline and 8wk

Interventionunits on a scale (Mean)
Acamprosate6.12

[back to top]

Alcohol Craving Rating in Response to Saline Infusion

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion

InterventionUnits on a scale (Mean)
Acamprosate1.704
Placebo1.766

[back to top]

Alcohol Craving Rating in Response to Yohimbine Infusion

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion

InterventionUnits on a scale (Mean)
Acamprosate3.613
Placebo3.606

[back to top]

Alcohol Craving Rating in Response to Meta-Chlorophenylpiperazine

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion

InterventionUnits on a scale (Mean)
Acamprosate3.460
Placebo5.416

[back to top]

Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Acamprosate or Naltrexone or Placebo During the Double-Blind Period

The four Visual Analog Scale questions assess domains of alcohol craving: the intention to drink, loss of control, relief craving, and urge intensity. The scale ranges from 0-20 where a zero indicates no craving and 20 indicates severe craving; thus, a higher score indicates a worse outcome. Total is a summation of the four subscales (i.e. Strength, Intent, Impulse, Relief) and ranges in value from 0-80 with higher scores indicative of a worse outcome. (NCT00656630)
Timeframe: 1 week

,,
Interventionunits on a scale (Mean)
StrengthIntentImpulseReliefTotal
Campral (Acamprosate)2.121.651.170.075.00
ReVia (Naltrexone)3.402.991.692.0110.09
Sugar Pill (Placebo)5.864.224.313.5717.96

[back to top]

Change From Screening in Craving on the Alcohol Craving Questionnaire-Short Form (ACQ-SF) Total Score at Week 1

The ACQ-SF is an assessment of current drinking urges, difficulty resisting urge and anticipation of positive outcome or relief from negative state by drinking. The Total score ranges from 0 to 7 where a lower score is a better outcome. Change = (Week 1 score - Screening score). The scale is comprised of twelve items (range 0-7) that are averaged to compute the Total score. (NCT00656630)
Timeframe: 2 weeks

,,
Interventionunits on a scale (Mean)
ACQ-SF Total ScreeningACQ-SF Total Week 1ACQ-SF Total Change
Campral (Acamprosate)3.803.36-0.44
ReVia (Naltrexone)3.813.69-0.12
Sugar Pill (Placebo)3.993.51-0.48

[back to top]

Change From Baseline in Standard Drinks Per Week at 1 Week

Standard drinks are equivalent to 14 grams of pure alcohol and number of drinks are assessed with Timeline Follow-Back (TLFB) methods. Change = (Week 1 - Baseline). More negative values indicate less use of alcohol. (NCT00656630)
Timeframe: 1 week

,,
Interventiondrinks/week (Mean)
Drinks/week BaselineDrinks/week Week 1Drinks/week Change
Campral (Acamprosate)44.9024.37-20.53
ReVia (Naltrexone)47.0225.79-21.23
Sugar Pill (Placebo)48.8721.51-27.35

[back to top]

Change From Baseline in Mood on the Beck Depression Inventory (BDI-II) at Week 1

The BDI-II is a self-rating of severity of depressive symptoms. BDI-II Total scores range from 0-63; a lower score indicates less severe depressive systems and thus is a better outcome. Change = (Week 1 score - Baseline score). The Total score is a sum of the 21 items on the BDI-II instrument, with each item rated from 0-3. (NCT00656630)
Timeframe: 1 week

,,
Interventionunits on a scale (Mean)
BDI-II Total BaselineBDI-II Total Week 1BDI-II Total Change
Campral (Acamprosate)4.404.750.35
ReVia (Naltrexone)4.043.84-0.20
Sugar Pill (Placebo)3.534.941.41

[back to top]

Change From Baseline in Sleep Quality on the Pittsburgh Sleep Quality Index (PSQI) Total Score at Week 1

The PSQI is an instrument to assess subjective sleep quality and disturbance. The Total score ranges from 0 to 21 where a lower score is better sleep quality. Change = (Week 1 score - Baseline score). Seven subscales (range 0-3) are summed to compute the Total score. (NCT00656630)
Timeframe: 1 week

,,
Interventionunits on a scale (Mean)
PSQI Total BaselinePSQI Total Week 1PSQI Total Change
Campral (Acamprosate)4.504.690.19
ReVia (Naltrexone)4.744.57-0.17
Sugar Pill (Placebo)4.254.380.13

[back to top]

Anterior Cingulate Cortex - Creatinine

"Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse5.465.09-0.14
No ETOH Abuse5.125.160.07

[back to top]

Left Dorsal Lateral Prefrontal Cortex - N-acetylaspartate

"N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse7.227.440.25
No ETOH Abuse7.508.040.16

[back to top]

Anterior Cingulate Cortex - Choline

"Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse1.641.46-0.10
No ETOH Abuse1.541.580.04

[back to top]

Fractional Anisotropy Measured With Diffusion Tensor Imaging

Diffusion Tensor Imaging Frational Anisotropy (FA) Measures by Lifetime History of Alcohol Abuse/Dependence and Brain Hemisphere. (NCT00688324)
Timeframe: Completion of two scans

,
InterventionFA (Mean)
Right hemisphereLeft hemisphere
ETOH Abuse0.630.59
No ETOH Abuse0.610.57

[back to top]

SANS - Negative Symptoms of Schizophrenia Total Score

Negative symptoms of schizophrenia measured using the Scale for the Assessment of Negative Symptoms (SANS) Total Score. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms. (NCT00688324)
Timeframe: Baseline (Treatment Week 0) and End of Study (Treatment Week 2)

,
Interventionunits on a scale (Mean)
BaselineEnd of studyChange
ETOH Abuse23.5024.182.091
No ETOH Abuse26.1226.38-0.375

[back to top]

Right Dorsal Lateral Prefrontal Cortex - N-acetylaspartate

"N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse7.437.650.35
No ETOH Abuse7.658.150.42

[back to top]

Right Dorsal Lateral Prefrontal Cortex - Myo-inositol

"Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse3.733.41-0.17
No ETOH Abuse3.713.44-0.24

[back to top]

Right Dorsal Lateral Prefrontal Cortex - Glutamate

"Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse6.896.63-0.44
No ETOH Abuse7.517.15-0.69

[back to top]

Right Dorsal Lateral Prefrontal Cortex - Creatinine

"Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse5.515.520.27
No ETOH Abuse5.485.540.11

[back to top]

Right Dorsal Lateral Prefrontal Cortex - Choline

"Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Right Dorsal Lateral Prefrontal Cortex (R DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse1.361.320.06
No ETOH Abuse1.301.710.40

[back to top]

Left Dorsal Lateral Prefrontal Cortex - Myo-inositol

"Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse3.693.34-0.08
No ETOH Abuse3.614.080.51

[back to top]

Left Dorsal Lateral Prefrontal Cortex - Glutamate

"Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse7.456.86-0.50
No ETOH Abuse6.986.920.03

[back to top]

Left Dorsal Lateral Prefrontal Cortex - Creatinine

"Creatinine brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse5.385.430.15
No ETOH Abuse5.785.860.11

[back to top]

Left Dorsal Lateral Prefrontal Cortex - Choline

"Choline brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Left Dorsal Lateral Prefrontal Cortex (L DLPFC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse1.531.570.05
No ETOH Abuse1.531.650.10

[back to top]

Anterior Cingulate Cortex - N-acetylaspartate

"N-acetylaspartate (NAA) brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse6.406.06-0.23
No ETOH Abuse5.996.140.15

[back to top]

Cognitive Impairment

"Cognitive tests will include the DigitSymbol Test (evaluating processing speed), California Verbal Learning Test (CVLT; evaluating verbal learning and episodic memory), and NBack (evaluating working memory).~Digit Symbol scaled scores range from 1 to 19, with the larger numbers indicating better performance.~On the CVLT, the delayed recognition score ranges from 0 to 16, with the larger numbers indicating better performance.~On the NBack test, subjects were asked to recall items 0-back, 1-back, and 2-back in a sequence. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower." (NCT00688324)
Timeframe: Change from Baseline (Treatment Week 0) to End of Study (Treatment Week 2)

,
Interventionunits on a scale (Mean)
Change in NBack 0-Back Total HitsChange in NBack 1-Back Total HitsChange in NBack 2-Back Total HitsChange in DigitSymbol Scaled ScoreChange in CVLT Total Recall
ETOH Abuse0.0000.601.70-0.20-0.600
No ETOH Abuse0.2141.141.710.00-0.143

[back to top]

BPRS - Symptoms of Psychosis Total Score

"The psychosis total score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from 1=Not Present to 7=Very Severe. The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating." (NCT00688324)
Timeframe: Baseline (Treatment Week 0) and End of Study (Treatment Week 2)

,
Interventionunits on a scale (Mean)
BaselineEnd of studyChange
ETOH Abuse8.888.82-1.00
No ETOH Abuse9.478.38-1.31

[back to top]

BPRS - Symptoms of Psychosis Change in Scores

"Symptoms of psychosis were measured with the Brief Psychiatric Rating Scale (BPRS). The items rated for psychosis are Conceptual Disorganization, Suspiciousness, Hallucinatory Behavior, and Unusual Thought Content. Each item score ranges from 1=Not Present to 7=Very Severe.~Value at End of Study minus value at Baseline." (NCT00688324)
Timeframe: Baseline (Treatment Week 0) and End of Study (Treatment Week 2)

,
Interventionunits on a scale (Mean)
Conceptual Disorganization ChangeSuspiciousness ChangeHallucinations ChangeUnusual Thought Content Change
ETOH Abuse-0.182-0.636-0.0909-0.0909
No ETOH Abuse0.0-0.532-0.6250-0.1250

[back to top]

Anterior Cingulate Cortex - Myo-inositol

"Myo-inositol brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse4.344.00-0.17
No ETOH Abuse4.004.350.20

[back to top]

Anterior Cingulate Cortex - Glutamate

"Glutamate brain metabolite levels between those with and without a lifetime history of prior alcohol abuse/dependence in the Anterior Cingulate Cortex (ACC) using Magnetic Resonance Spectroscopy (MRS). Metabolite concentration was calculated from the MRS signals and reported in mM." (NCT00688324)
Timeframe: Baseline screening (Scan 1) and again after 2 weeks of Acamprosate treatment (Scan 2)

,
InterventionmM (Mean)
Scan 1Scan 2Difference
ETOH Abuse7.447.06-0.25
No ETOH Abuse6.687.050.26

[back to top]

Social Responsiveness Scale

The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The score of each individual item is summed to create a total raw score. A total scores results are as follows: 0-62: Within normal limits 63-79: Mild range of impairment 80-108: Moderate range of impairment 109-149: Severe range of impairment (NCT01300923)
Timeframe: Week 10

Interventionunits on a scale (Mean)
Acamprosate Treatment Group76.4

[back to top]

Clinical Global Impression- Severity Scale (CGI-S)

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. (NCT01300923)
Timeframe: Week 10

Interventionunits on a scale (Mean)
Acamprosate Treatment Group7.0

[back to top]

Children's Yale-Brown Obsessive Compulsive Scale Modified for PDD

The Children's Yale-Brown Obsessive Compulsive Scales-Modified (CY-BOCS) is a 5-item, semi-structured clinician rating scale modified designed to rate the current severity of repetitive behavior in children and adolescents with PDD. Once the current repetitive behaviors are identified, they are separately rated on 5 items: Time Spent, Interference, Distress, Resistance, and Control. Each of these items is scored on a 5-point scale form 0 (least symptomatic) to 4 (most symptomatic). The CY-BOCS yields a Total Score from 0 to 20 and is sensitive to change. (NCT01300923)
Timeframe: Week 10

Interventionunits on a scale (Mean)
Acamprosate Treatment Group9.8

[back to top]

The Aberrant Behavior Checklist (ABC)

The Aberrant Behavior Checklist (ABC) is a 58-item rating scale used to assess maladaptive behaviors across five original subscales: Irritability (15 items from 0-45), Social Withdrawal (16 items from 0-48), Stereotypy (7 items from 0-21), Hyperactivity (16 items from 0-48), Inappropriate Speech (4 items from 0-12). Additionally, Social Avoidance, a newly developed four-item subscale (from 0-12) of the ABC that captures core social avoidance aspects of Fragile X Syndrome is reported. All items on the ABC are rated from 0 (not at all a problem) to 3 (the problem is severe in degree). Higher scores indicate greater maladaptive behaviors. Differences between Baseline and Week 10 are used as an indicator of change. (NCT01300923)
Timeframe: Week 10

Interventionunits on a scale (Mean)
ABC IrritabilityABC Social WithdrawalABC StereotypyABC HyperactivityABC Inappropriate SpeechABC Social Avoidance
Acamprosate Treatment Group7.04.16.011.04.81.6

[back to top]

Peabody Picture Vocabulary

The Peabody Picture Vocabulary Test is one of the most commonly used assessment tests that measure verbal ability in standard American English vocabulary. This test has been nationally standardized using examinees from various age groups, from children to adults. Thus, the raw scores are equated to mental age, using the norms obtained from standardization. The total standard scores range from 40 (worse receptive vocabulary) to 160 (better receptive vocabulary). The scores can also be converted to percentile rank. (NCT01300923)
Timeframe: Week 10

Interventionunits on a scale (Mean)
Acamprosate Treatment Group83.3

[back to top]

ADHD Rating Scale 4th Edition

The ADHD Rating Scale is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder. The ADHD Rating Scale-IV is completed by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. The total score can range from 0 to 54, with a higher score indicating greater severity. (NCT01300923)
Timeframe: Week 10

Interventionunits on a scale (Mean)
Acamprosate Treatment Group16.7

[back to top]

Brain-derived Neurotrophic Factor (BDNF)

BDNF is a protein that supports the survival of existing neurons and growth and differentiation of new neurons and synapses. (NCT01300923)
Timeframe: Screen and Week 10

Interventionpg/mL (Mean)
Acamprosate Treatment Group1,007.6

[back to top]

Vineland Adaptive Behavior Scales-II (VABS-II) Communication Domain

The VABS-II is a semi-structured interview designed to assess adaptive functioning in communication, daily living, socialization and motor skills. Recognizing that language is a major area of impairment in the study population, the Communication Domain (99 Items from 0-198), in particular the Expressive Subdomain (54 Items from 0-108) are of interest in this study. Items arranged in a developmental sequence are rated on a 3-point scale. Each item is scored from 0 (never performs the behavior) to 3 (usually performs the behavior independently). Higher scores indicate higher adaptive functioning. Differences between Baseline and Week 10 are used as an indicator of change. (NCT01300923)
Timeframe: Week 10

Interventionunits on a scale (Mean)
Communication DomainExpressive Communication
Acamprosate Treatment Group66.678.9

[back to top]

Change in EEG Relative Gamma Power

EEG relative gamma power at rest was calculated as the percent of power in the gamma frequencies relative to the sum of power in all frequency bands, averaged across electrodes, and calculated separately at pre-dose and post-dose timepoints. To assess the impact of drug, the pre-dose relative gamma power was subtracted from post-dose relative gamma power. Higher numbers indicate more relative gamma power post-dose; lower numbers indicate more relative gamma power pre-dose. (NCT02998151)
Timeframe: Pre-dose, 4-hour post-dose

Interventionpercent of power in gamma frequencies (Mean)
Placebo0.0024
Acamprosate-0.0077
Lovastatin-0.0039
Minocycline0.0019
Baclofen-0.0160

[back to top]

Woodcock Johnson Test of Cognitive Abilities - Auditory Attention Task

Woodcock Johnson Test of Cognitive Abilities III Auditory Attention subscale. Participants must identify orally presented words amid increasingly intense background noise. The scores for this subtask range from 0-50, with higher scores indicating a better outcome. Raw scores for this subscale are reported (rather than standard scores, or age- or grade-equivalents). (NCT02998151)
Timeframe: 4-hour post-dose

Interventionscore on a scale (Mean)
Placebo32.84
Acamprosate33.07
Lovastatin32.93
Minocycline33.24
Baclofen33

[back to top]

Test of Attentional Performance for Children (KiTAP) Test of Alertness

Computerized task where an examinee is required to push a key when a target stimulus is presented on the screen. Scores are presented as change in median reaction time (RT), in milliseconds. (NCT02998151)
Timeframe: Predose, 4-hour post-dose

Interventionchange in median RT in milliseconds (Mean)
Placebo13.76
Acamprosate-28.64
Lovastatin18.59
Minocycline26.85
Baclofen-31.44

[back to top]

Clinical Global Impressions-Improvement

The Clinical Global Impressions - Improvement (CGI-I) requires the clinician to assess how much the patient's illness has changed relative to pre-dose, from 1 (very much improved) to 7 (very much worse). (NCT02998151)
Timeframe: 4-hour post-dose

Interventionscore on a scale (Mean)
Placebo3.70
Acamprosate3.88
Lovastatin3.97
Minocycline3.81
Baclofen3.94

[back to top]

Change From Pre-dose in the Repeatable Battery for the Assessment of Neuropsychological Status at 4 Hours Post Dose

Four 10-item lists of unrelated words were presented orally to the examinee who was then required to immediately recall words presented, at both pre-dose and post-dose timepoints. The impact of drug was assessed by subtracting the number of words remembered post-dose from the number of words remembered pre-dose. Lower numbers indicate more words remembered post-dose; higher numbers indicate more words remembered pre-dose. (NCT02998151)
Timeframe: Pre-dose, 4-hour post dose

Interventionnumber of words remembered (Mean)
Placebo-.20
Acamprosate-1.47
Lovastatin-1.25
Minocycline-.69
Baclofen-.88

[back to top]